LAUSANNE, Switzerland, Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial ...
ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, expectations were $-0.35. Operator: Good ...
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results